A man in his 30s recently presented to a Shanghai hospital with a draining facial fistula—a visible skin opening on his cheek discharging purulent exudate—after years of untreated recurrent pericoronitis around an impacted third molar. Imaging and clinical evaluation confirmed that the infection had extended beyond the alveolar bone into adjacent facial soft tissues, resulting in cutaneous breakdown. Following aggressive surgical debridement and systemic antimicrobial therapy, clinicians successfully controlled the infection and extracted the offending wisdom tooth. This intervention prevented permanent scarring and underscored a critical clinical lesson: recurrent pericoronitis is not merely a nuisance—it is a progressive infectious process with potentially serious local complications.
Pericoronitis—the inflammation of the soft tissue surrounding a partially erupted or impacted mandibular third molar—is among the most common oral surgical emergencies. When left unaddressed, it can escalate from localized gingival swelling and trismus to cellulitis, abscess formation, deep space infections, and, as in this case, cutaneous fistulization. Clinical red flags demanding prompt referral and definitive management—including extraction—include persistent or worsening pain, progressive facial swelling, limited mouth opening, fever, and spontaneous drainage through the skin or intraorally.
Postoperative management remains a key determinant of patient recovery and satisfaction. Following third molar extraction for active pericoronitis, patients commonly experience moderate-to-severe localized pain, edema, and functional impairment due to both surgical trauma and residual inflammatory activity. Optimizing postoperative care therefore requires a multimodal strategy—one that addresses analgesia, infection control, and wound healing simultaneously.
In this context, topical pharmacotherapy offers a targeted, low-systemic-risk option for managing localized discomfort. A growing body of evidence supports the use of compound chamomile-lidocaine gel (brand name Ganmeida®) as an adjunctive treatment following third molar surgery. This water-soluble oral gel combines lidocaine (a fast-acting local anesthetic), thymol (a broad-spectrum antimicrobial agent), and chamomile tincture (with anti-inflammatory and tissue-repair properties).
Clinical studies demonstrate its efficacy across three therapeutic domains. First, as a topical anesthetic, the lidocaine component provides rapid-onset, localized pain relief—particularly valuable for superficial mucosal or gingival wound pain. A comparative clinical trial found that compound chamomile-lidocaine gel delivered superior surface analgesia compared with standard comparator agents in dental procedures, supporting its utility in post-extraction care.
Second, thymol—present at 1.0 mg/g—exerts potent antibacterial, antifungal, and antiviral activity. Notably, its antimicrobial potency exceeds that of phenol, while its systemic toxicity is only one-quarter that of phenol, making it both effective and well-tolerated in oral applications. In a randomized clinical study involving patients with acute pericoronitis, those treated with the gel showed significantly faster resolution of inflammation, reduced pain scores, shorter overall treatment duration, and fewer follow-up visits compared with controls.
Third, preclinical research in Sprague-Dawley rats confirms that the formulation actively modulates the wound-healing cascade: it suppresses pro-inflammatory cytokine expression at extraction sites and accelerates soft-tissue re-epithelialization and collagen deposition—key markers of efficient mucosal repair.
While systemic NSAIDs and antibiotics remain foundational in moderate-to-severe cases, topical agents like compound chamomile-lidocaine gel represent a valuable addition to the armamentarium—especially for patients experiencing localized, non-systemic symptoms. Its triple-action profile—analgesic, antimicrobial, and pro-healing—makes it particularly suited for early postoperative symptom control after third molar removal for pericoronitis.
Complementary nonpharmacologic measures are equally essential. Patients should apply ice packs intermittently (15–20 minutes on, ≥60 minutes off) during the first 24 hours to minimize edema. Diet should consist of cool, soft, non-irritating foods for 48–72 hours; hot, spicy, crunchy, or acidic items must be avoided to prevent wound irritation or hemorrhage. Gentle saline or alcohol-free antimicrobial rinses may begin 24 hours postoperatively—but vigorous swishing must be avoided. Patients should also refrain from strenuous activity and sleep with the head slightly elevated to reduce hydrostatic pressure and promote venous/lymphatic drainage.
This case serves as a timely reminder: asymptomatic or intermittently symptomatic impacted third molars warrant proactive evaluation—not passive observation. Early intervention prevents progression to complex, disfiguring, and resource-intensive complications. And when surgery is indicated, evidence-informed, multimodal postoperative care—including judicious use of targeted topical therapeutics—can meaningfully improve outcomes, comfort, and recovery trajectories.